Acumen Pharma (ABOS) Jumps 4.73% to $2.02, Surpassing 200‑Day Average and Nearing $3.60 Peak
Acumen Pharm’s ABOS stock rises 4.73%, beating its 200‑day SMA while eyeing Phase‑2 Alzheimer’s data that could spark a surge.
- ACUMEN PHARMACEUTICALS INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read